Sumant Kulkarni
Stock Analyst at Canaccord Genuity
(1.95)
# 3,104
Out of 4,908 analysts
115
Total ratings
35.71%
Success rate
-8.14%
Average return
Main Sectors:
Stocks Rated by Sumant Kulkarni
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYBN Cybin | Maintains: Buy | $73 → $70 | $7.73 | +805.56% | 8 | Jul 8, 2025 | |
| ATAI Atai Life Sciences | Maintains: Buy | $11 → $12 | $3.53 | +239.94% | 2 | Jul 2, 2025 | |
| SAGE Sage Therapeutics | Maintains: Hold | $8 → $8.5 | $8.75 | -2.86% | 7 | Jun 17, 2025 | |
| ANVS Annovis Bio | Maintains: Buy | $26 → $17 | $2.57 | +561.48% | 3 | May 15, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $158 → $160 | $132.75 | +20.53% | 16 | May 6, 2025 | |
| BIIB Biogen | Maintains: Buy | $265 → $220 | $127.85 | +72.08% | 21 | May 2, 2025 | |
| CRVO CervoMed | Maintains: Buy | $12 → $21 | $8.25 | +154.55% | 5 | Mar 18, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $23 → $25 | $11.58 | +115.98% | 6 | Mar 13, 2025 | |
| VYGR Voyager Therapeutics | Maintains: Buy | $14 → $12 | $3.16 | +279.75% | 5 | Mar 13, 2025 | |
| CMPS COMPASS Pathways | Maintains: Buy | $23 → $15 | $4.42 | +239.37% | 3 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $112 → $80 | $1.81 | +4,332.13% | 7 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $28 | $16.69 | +67.77% | 4 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $86 → $83 | $3.81 | +2,078.48% | 5 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $14 | $9.64 | +45.23% | 1 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $20 | $13.57 | +47.38% | 3 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $33 | $22.57 | +46.21% | 13 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $101 → $150 | $13.43 | +1,016.90% | 4 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $16.29 | - | 2 | Jan 31, 2017 |
Cybin
Jul 8, 2025
Maintains: Buy
Price Target: $73 → $70
Current: $7.73
Upside: +805.56%
Atai Life Sciences
Jul 2, 2025
Maintains: Buy
Price Target: $11 → $12
Current: $3.53
Upside: +239.94%
Sage Therapeutics
Jun 17, 2025
Maintains: Hold
Price Target: $8 → $8.5
Current: $8.75
Upside: -2.86%
Annovis Bio
May 15, 2025
Maintains: Buy
Price Target: $26 → $17
Current: $2.57
Upside: +561.48%
Neurocrine Biosciences
May 6, 2025
Maintains: Buy
Price Target: $158 → $160
Current: $132.75
Upside: +20.53%
Biogen
May 2, 2025
Maintains: Buy
Price Target: $265 → $220
Current: $127.85
Upside: +72.08%
CervoMed
Mar 18, 2025
Maintains: Buy
Price Target: $12 → $21
Current: $8.25
Upside: +154.55%
Zevra Therapeutics
Mar 13, 2025
Maintains: Buy
Price Target: $23 → $25
Current: $11.58
Upside: +115.98%
Voyager Therapeutics
Mar 13, 2025
Maintains: Buy
Price Target: $14 → $12
Current: $3.16
Upside: +279.75%
COMPASS Pathways
Feb 28, 2025
Maintains: Buy
Price Target: $23 → $15
Current: $4.42
Upside: +239.37%
Jan 6, 2025
Maintains: Buy
Price Target: $112 → $80
Current: $1.81
Upside: +4,332.13%
Nov 18, 2024
Maintains: Buy
Price Target: $31 → $28
Current: $16.69
Upside: +67.77%
Nov 14, 2024
Maintains: Buy
Price Target: $86 → $83
Current: $3.81
Upside: +2,078.48%
Sep 16, 2024
Maintains: Buy
Price Target: $16 → $14
Current: $9.64
Upside: +45.23%
May 7, 2024
Maintains: Buy
Price Target: $21 → $20
Current: $13.57
Upside: +47.38%
Mar 12, 2024
Maintains: Buy
Price Target: $40 → $33
Current: $22.57
Upside: +46.21%
Aug 3, 2021
Maintains: Buy
Price Target: $101 → $150
Current: $13.43
Upside: +1,016.90%
Jan 31, 2017
Upgrades: Buy
Price Target: n/a
Current: $16.29
Upside: -